Systems Analyses of the Immune Response to the Seasonal Influenza Vaccine

Condition:   Healthy Volunteer Interventions:   Biological: Flucelvax;   Biological: Fluvirin;   Biological: Fluzone High Dose Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Condition:   Healthy Volunteer Interventions:   Biological: Flucelvax;   Biological: Fluvirin;   Biological: Fluzone High Dose Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractPurpose of ReviewAnaphylaxis is a rare, serious hypersensitivity reaction following vaccination, which is rapid in onset and characterized by multisystem involvement. Although anaphylaxis may occur after any vaccine, understanding the risk for this outcome, particularly following influenza vaccines, is important because of the large number of persons vaccinated annually.Recent FindingsTwo recent CDC safety studies confirmed the rarity of post-vaccination anaphylaxis. In a 25-year review of data from the Vaccine Adverse Event Reporting System (VAERS), reports in children were most common following childhood vaccinat...
Source: Current Treatment Options in Allergy - Category: Allergy & Immunology Source Type: research
(NIH/National Institute of Allergy and Infectious Diseases) A study of influenza virus transmission in Nicaraguan households reveals new insights into the type of immune responses that may be protective against influenza virus infection, report investigators. The findings could help scientists design more effective influenza vaccines and lead to the development of novel universal influenza vaccines. The research was funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
(NIH/National Institute of Allergy and Infectious Diseases) The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, has announced two awards for the study of influenza immunity in children. The awards, which may total more than $64 million over seven years, will support studies led by Cincinnati Children's Hospital Medical Center and St. Jude Children's Research Hospital, examining how young children's immune systems respond over multiple years to their initial influenza infection and their first vaccination.
Source: EurekAlert! - Infectious and Emerging Diseases - Category: Infectious Diseases Source Type: news
Conditions:   Influenza;   Influenza Immunisation Interventions:   Biological: Advax-CpG55.2;   Drug: AF03;   Biological: Influenza Virus Quadrivalent Inactivated Vaccine;   Biological: Quadrivalent Recombinant Seasonal Influenza Vaccine Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Allergy | Allergy & Immunology | Infectious Diseases | Influenza | Influenza Vaccine | Research | Vaccines